A drug that reaches a pharmacy shelf today often rests on discoveries made decades earlier. That gap between scientific effort and clinical result creates a funding problem. Grants operate on defined timetables. Breakthroughs in neurodegenerative disease frequently don’t.

Jean-Pierre Conte committed $5 million to the University of California, San Francisco in November 2024 to establish two endowed professorships in the Department of Neurology. The positions support Parkinson’s and neurodegenerative disease research. The cause carries personal weight: his father, Pierre Conte, was diagnosed with Parkinson’s in his mid-70s and received care from a team of UCSF physicians.

“UCSF is an incredible place – the #1 recipient of NIH funding, with some of the most highly regarded clinician-scientists working to improve treatments for Parkinson’s and other diseases,” Conte said in remarks published by the university.

Endowed professorships function differently from conventional research grants. Rather than financing a single project for a fixed term, an endowment generates continuing financial support for faculty research, teaching, and academic infrastructure. Researchers in fields requiring cumulative, multi-decade observation can benefit from that structure in ways that grant-funded colleagues often can’t.

Parkinson’s illustrates the gap clearly. The disease has no cure. Research threads are spread across genetics, clinical observation, drug development, and early-detection tools. Progress in any one thread can take years to translate across the others. Sustained institutional backing, the kind an endowment provides, helps researchers stay on those threads rather than reorienting their work toward what’s fundable in a given grant cycle. An Impakter profile of Jean-Pierre Conte published in August 2026 examined his philanthropic approach and the J-P Conte Family Foundation, which he founded in 2017. As managing partner of a San Francisco middle-market private equity firm, Conte brings the same long-hold perspective to his giving that has characterized his investment career.